Full Press Release Details
In this poster presented at AACR, the research team describes findings from analyses of EIK1001 pharmacokinetics (PK) and cytokine biomarker data from two Phase 1 clinical trials in participants with advanced solid tumors. PK is linear and dose-proportional. Dose-dependent increases in IP-10 and IFNg are consistent with the TLR7/8 mechanism of action, over a dose range where clinical response was observed in the heavily treated and heterogenous Phase 1 population. These analyses support the design of future clinical trials including dose optimization.
View the AACR poster her e .
D. Rasco, M. Patel, M. Johnson, A. Tolcher, D. Sommerhalder, O. Hamid, A. Alistar, J. Kochan, E. Kurland, M. Wang, C. Cho, S. Rebello. Pharmacokinetic/biomarker (PK/BMx) analysis of the toll-like receptor 7 and 8 (TLR7/8) agonist EIK1001 in phase 1 studies in participants (Pts) with solid tumors [abstract]. In: Proceedings of the 115th Annual Meeting of the American Association for Cancer Research; 2024 April 5-10; San Diego, CA. Philadelphia (PA): AACR; 2024. Abstract nr 7172. ( https://www.abstractsonline.com/pp8/#!/20272/presentation/8036 )